US Patent 11576895 Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
Patent 11576895 was granted and assigned to EpicentRx on February, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 14 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 7 Sep, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 25 Apr, 2023
Golden AI
Infobox
Edits on 24 Mar, 2023
Golden AI
Edits on 22 Mar, 2023
Golden AI
Infobox
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
115768950
Date of Patent
February 14, 2023
0Patent Application Number
160690120
Date Filed
January 11, 2017
0Patent Citations
Patent Primary Examiner
CPC Code
Edits on 15 Feb, 2023
Golden AI
Edits made to:
Infobox (+15 properties)
Article (+328 characters)
US Patent 11576895 Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
Article
The invention provides compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), including formulations containing autologous whole blood and ABDNAZ that can be rapidly administered to a patient by intravenous infusion without any significant pain at the site of infusion.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
115768950
Date of Patent
February 14, 2023
0Patent Application Number
160690120
Date Filed
January 11, 2017
0Patent Citations
Patent Primary Examiner
CPC Code
Find more entities like US Patent 11576895 Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
